Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the target of a large increase in short interest in June. As of June 30th, there was short interest totaling 27,461 shares, an increase of 79.6% from the June 15th total of 15,293 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 67,600 shares, the days-to-cover ratio is presently 0.4 days.
Tema Oncology ETF Price Performance
Shares of NASDAQ:CANC opened at $40.51 on Friday. Tema Oncology ETF has a 1 year low of $25.12 and a 1 year high of $42.63. The business’s 50-day moving average is $38.69 and its 200-day moving average is $37.45. The company has a market capitalization of $192.02 million, a price-to-earnings ratio of 20.39 and a beta of 0.67.
Institutional Trading of Tema Oncology ETF
A number of hedge funds have recently bought and sold shares of the business. Thrivent Financial for Lutherans increased its holdings in Tema Oncology ETF by 891.1% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock valued at $50,747,000 after purchasing an additional 1,314,177 shares during the period. LPL Financial LLC purchased a new stake in Tema Oncology ETF in the 4th quarter worth approximately $278,000. Roxbury Financial LLC lifted its holdings in Tema Oncology ETF by 326.4% in the 2nd quarter. Roxbury Financial LLC now owns 3,940 shares of the company’s stock worth $162,000 after buying an additional 3,016 shares during the period. Jane Street Group LLC bought a new stake in shares of Tema Oncology ETF in the 4th quarter worth approximately $1,100,000. Finally, Flow Traders U.S. LLC bought a new stake in shares of Tema Oncology ETF in the 3rd quarter worth approximately $630,000.
Tema Oncology ETF Company Profile
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
Featured Stories
- Five stocks we like better than Tema Oncology ETF
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
